GeNeuro Announces Participation at Upcoming Investor Events

Regulatory News:

GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), today announced that management will participate in the upcoming investor events outlined below:

• NewsMakers in the Biotech Industry 2016, September 9 2016 - New York, USA
• Rodman & Renshaw 18th Annual Healthcare Conference, September 12 & 13, 2016 - New York, USA
• 16th Sachs Annual Biotech in Europe Forum, September 27 and 28, 2016 - Basel, Switzerland
• Mid Cap Event, October 5 & 6, 2016 - Paris, France

Next financial communication

Financial results for the first six months of 2016 and business update: September 29, 2016 after market close

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA; a new frontier pioneered by GeNeuro since 2006 and based on research by Institut Mérieux and INSERM.

GeNeuro's first product, GNbAC1, is the first drug candidate in clinical studies directly targeting a potential cause of MS. It is designed to neutralize MSRV-Env, a protein linked to the inflammatory and neurodegenerative components of the disease and could represent a paradigm shift in the options for treating multiple sclerosis. GNbAC1 is being developed under a collaboration agreement for the rights ex US and Japan with Servier that could generate, excluding royalties, over €360 million in revenue for GeNeuro, €37.5 million of which is allocated to financing the ongoing Phase IIb clinical trial in this disease.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in France at sites in Archamps, Haute-Savoie and Lyon. It has 23 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160905005494/en/